861 related articles for article (PubMed ID: 24598590)
21. Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.
Niemann J; Woller N; Brooks J; Fleischmann-Mundt B; Martin NT; Kloos A; Knocke S; Ernst AM; Manns MP; Kubicka S; Wirth TC; Gerardy-Schahn R; Kühnel F
Nat Commun; 2019 Jul; 10(1):3236. PubMed ID: 31324774
[TBL] [Abstract][Full Text] [Related]
22. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory.
Hinterberger M; Giessel R; Fiore G; Graebnitz F; Bathke B; Wennier S; Chaplin P; Melero I; Suter M; Lauterbach H; Berraondo P; Hochrein H; Medina-Echeverz J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579736
[No Abstract] [Full Text] [Related]
24. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
25. Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma.
Meng G; Li B; Chen A; Zheng M; Xu T; Zhang H; Dong J; Wu J; Yu D; Wei J
Br J Cancer; 2020 Jan; 122(1):111-120. PubMed ID: 31819179
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
27. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
Engeland CE; Grossardt C; Veinalde R; Bossow S; Lutz D; Kaufmann JK; Shevchenko I; Umansky V; Nettelbeck DM; Weichert W; Jäger D; von Kalle C; Ungerechts G
Mol Ther; 2014 Nov; 22(11):1949-59. PubMed ID: 25156126
[TBL] [Abstract][Full Text] [Related]
28. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
29. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
Chen D; Huang L; Zhou H; Zhang Y
Front Immunol; 2021; 12():615089. PubMed ID: 33717103
[TBL] [Abstract][Full Text] [Related]
30. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses.
Zamarin D; Martínez-Sobrido L; Kelly K; Mansour M; Sheng G; Vigil A; García-Sastre A; Palese P; Fong Y
Mol Ther; 2009 Apr; 17(4):697-706. PubMed ID: 19209145
[TBL] [Abstract][Full Text] [Related]
32. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo.
Xu Q; Rangaswamy US; Wang W; Robbins SH; Harper J; Jin H; Cheng X
Int J Cancer; 2020 Jan; 146(2):531-541. PubMed ID: 31584185
[TBL] [Abstract][Full Text] [Related]
34. Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity.
Schwaiger T; Knittler MR; Grund C; Roemer-Oberdoerfer A; Kapp JF; Lerch MM; Mettenleiter TC; Mayerle J; Blohm U
Int J Cancer; 2017 Dec; 141(12):2505-2516. PubMed ID: 28857157
[TBL] [Abstract][Full Text] [Related]
35. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
[TBL] [Abstract][Full Text] [Related]
36. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
37. A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity.
Huang FY; Wang JY; Dai SZ; Lin YY; Sun Y; Zhang L; Lu Z; Cao R; Tan GH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759233
[TBL] [Abstract][Full Text] [Related]
38. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
Ricca JM; Oseledchyk A; Walther T; Liu C; Mangarin L; Merghoub T; Wolchok JD; Zamarin D
Mol Ther; 2018 Apr; 26(4):1008-1019. PubMed ID: 29478729
[TBL] [Abstract][Full Text] [Related]
39. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
40. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses.
Wang G; Kang X; Chen KS; Jehng T; Jones L; Chen J; Huang XF; Chen SY
Nat Commun; 2020 Mar; 11(1):1395. PubMed ID: 32170083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
